Vaginal Health in Perimenopause, Explained.

Everyone warned you about hot flashes. Nobody warned you that estrogen leaving would quietly change everything below the waist — until it did.

✓ Medically Reviewed — Michael Peters, MD

Reviewed 2026-05-17

"You are not broken. Your tissues changed. And nobody — not your GP, not your gynecologist, not your mother — prepared you for what estrogen leaving actually does to this part of your body."

Estrogen decline directly causes vaginal tissue thinning, loss of lubrication, and pelvic floor changes — producing symptoms that affect comfort, intimacy, bladder function, and identity. This is a biological event, not a personal failing.

Genitourinary Syndrome of Menopause (GSM) is the clinical term for the full constellation of vaginal, urethral, and pelvic floor changes driven by estrogen withdrawal — and it affects an estimated 50–70% of menopausal women, most of whom have never heard the term.

The gynecology appointment where nobody mentioned estrogen. The UTI that kept coming back with no explanation. The "just use more lubricant" advice that missed the entire mechanism. The years of tolerating pain during sex because you assumed it was just aging.

GSM has been treatable for decades. The conversation just never happened.

The term GSM was established by consensus in 2014 (Portman and Gass)¹ to replace the older term "vulvovaginal atrophy" — because atrophy described only part of the picture. The full syndrome affects the vagina, vulva, urethra, bladder, and pelvic floor simultaneously. All of these tissues have estrogen receptors. All of them change when estrogen declines.

Unlike hot flashes, which often improve over time as the body adapts to lower estrogen levels, GSM symptoms typically worsen without treatment. The tissue changes are progressive. Waiting does not help. When estrogen declines, it rarely affects only one system — brain fog and cognitive symptoms often compound the picture.

The VIVA survey (Nappi and Kokot-Kierepa, 2012)⁴ documented the scale of the underreporting problem: most women with GSM symptoms do not discuss them with their provider, and most providers do not screen proactively. The result is a condition that affects the majority of menopausal women and is treated in a minority of them.

For women who are candidates, vaginal estrogen therapy addresses the root hormonal cause of GSM — consult your physician to determine if this is appropriate for your clinical profile.

Estrogen receptors are distributed throughout the genitourinary tract — vaginal epithelium, urethral tissue, bladder trigone, pelvic floor muscles, and connective tissue. When estrogen declines, all of these tissues change simultaneously.

The vaginal epithelium thins from 15–20 cell layers to 5–7. Collagen production decreases. The rugae — the folds that allow the vaginal canal to expand — flatten. The vaginal pH rises from its protective acidic range (3.8–4.5) to above 5.0, disrupting the lactobacillus-dominant microbiome and creating vulnerability to bacterial overgrowth and recurrent infection.

The urethra shares the same estrogen-sensitive tissue. Estrogen withdrawal thins the urethral epithelium, reduces urethral closure pressure, and disrupts the bladder's protective lining. This is why bladder urgency, frequency, stress incontinence, and recurrent UTIs often arrive alongside vaginal symptoms — they share the same hormonal root. The same estrogen withdrawal that drives GSM also drives persistent fatigue and energy depletion through mitochondrial bioenergetics.

The pelvic floor muscles and connective tissue also have estrogen receptors. Estrogen withdrawal reduces the elasticity of the connective tissue that supports pelvic organs, contributing to pelvic heaviness, pressure, and — in more advanced cases — pelvic organ prolapse. Pelvic floor exercises maintain muscle tone but do not address the underlying tissue changes driving the symptoms.

Lubricants address friction in the moment but do not restore tissue integrity. They treat the symptom of the symptom — the friction caused by tissue thinning — without addressing the tissue thinning itself. Using more lubricant is not a treatment for GSM. It is a workaround.

Increased sexual activity helps maintain blood flow to vaginal tissue and may slow some aspects of atrophy — but it does not replace estrogen-mediated tissue maintenance. The mechanism driving GSM is hormonal, not mechanical.

Pelvic floor exercises address muscle tone but not the underlying atrophic changes in vaginal tissue, urethral tissue, and connective tissue. They are a useful adjunct, not a primary treatment for GSM.

The standard toolkit — lubricant, Kegels, "just try to relax" — treats symptoms without addressing the estrogen withdrawal that is driving all of them simultaneously. The NAMS 2020 GSM position statement² is clear: vaginal estrogen is the most evidence-backed intervention for GSM. The conversation about why it is not the first thing offered to every woman with these symptoms is a different article. When you are ready to evaluate treatment options, comparing provider options is the practical next step.

The following table maps the primary GSM symptoms to their mechanisms and evidence-graded interventions. The critical first step is recognizing that these symptoms share a single hormonal root.

See a provider if you experience vaginal dryness, pain during intercourse, recurrent UTIs, or bladder urgency that is affecting your quality of life. Do not wait for symptoms to become severe before seeking care — GSM typically worsens without treatment.

"I've been experiencing vaginal dryness, discomfort during sex, and/or bladder symptoms since my periods became irregular. I'd like to discuss whether this is Genitourinary Syndrome of Menopause and what treatment options are appropriate for me — including whether vaginal estrogen is right for my situation."

1. Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society. Menopause. 2014;21(10):1063-1068.

   Why this matters: This consensus paper established the term 'Genitourinary Syndrome of Menopause' (GSM) to replace 'vulvovaginal atrophy' — recognizing that estrogen withdrawal affects not just vaginal tissue but the entire genitourinary tract including the urethra, bladder, and pelvic floor. The terminology shift matters clinically because it broadens the symptom picture providers should screen for.

2. The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992.

   Why this matters: The current NAMS clinical guideline for GSM. Establishes vaginal estrogen as the most evidence-backed intervention, documents the strong safety profile including in many breast cancer survivors, and endorses non-hormonal options including hyaluronic acid. This is the clinical consensus document that underpins the evidence tiers in this article.

3. Jokar A, et al. Comparison of the hyaluronic acid vaginal cream and conjugated estrogen used in treatment of vaginal atrophy of menopause women: a randomized controlled clinical trial. Iran J Pharm Res. 2016;15(Suppl):25-32.

   Why this matters: RCT comparing hyaluronic acid vaginal cream to conjugated estrogen for vaginal atrophy. Hyaluronic acid produced comparable improvements in vaginal dryness, pH, and maturation index — providing the evidence base for non-hormonal HA products as legitimate alternatives, not just palliative comfort measures.

4. Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) — results from an international survey. Climacteric. 2012;15(1):36-44.

   Why this matters: International survey documenting the underreporting gap — most women with GSM symptoms do not discuss them with their provider, and most providers do not screen proactively. This is the data behind the clinical invisibility of GSM that this article addresses directly.

5. Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13(6):509-522.

   Why this matters: International Menopause Society clinical recommendations covering the full spectrum of vaginal atrophy management — from lifestyle measures to hormonal and non-hormonal interventions. Provides the evidence grading framework referenced in the clinical table.

6. Crandall CJ, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause. 2018;25(1):11-20.

   Why this matters: WHI observational data on vaginal estrogen safety — no significant increase in breast cancer, endometrial cancer, or cardiovascular events. This is the key safety data that supports the NAMS position that vaginal estrogen has a strong safety profile distinct from systemic HRT.